CIEP: An oral chemotherapy regimen devised for diffuse large cell lymphoma (DLCL) in elderly patients: An interim report from Italian lymphoma intergroup (IIL).
2002 Merli, R; Bertini, M; Luminari, S; Botto, B; Tarantini, G; Freilone, R; Berte, R; Liberati, Anna Marina; Et, All
High clinical and molecular response rate in elderly patients with advanced stage follicular lymhoma treated at diagnosis with a brief chemo-immunotherapy FND plus Rituximab.
2002 Vitolo, U; Boccomini, C; Ladetto, M; Rota Scalabrini, D; Pogliani, E; Rigacci, L; Carpaneto, A; Liberati, Anna Marina
A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis.
2003 Vitolo, U; Boccomini, C; Ladetto, M; Pogliani, E; Scalabrini, Dr; Tarella, C; Castellino, C; Aglietta, M; Astolfi, M; Botto, B.; Carpaneto, A; Corradini, P; Darbesio, A; De Crescenzo, A; Levis, A; Liberati, Anna Marina
Aggressive non-Hodgkin's lymphoma (NHL) in elderly patients: An "age-adjusted" high dose chemotherapy (HDC) with ASCT is feasible and effective.
2003 Pregno, P; Botto, B; Liberati, Anna Marina
Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma.
2003 Palumbo, A; Bertola, A; Musto, P.; Nunzi, M; De Stefano, V; Callea, V; Rotoli, B; Petti, Mc; Caravita, T; Lauta, Vm; Patti, C; Bringhen, S; Cavallo, F; Falco, P; Carella, Am; Liberati, Anna Marina; Boccadoro, M.
A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis.
2004 Palumbo, A; Bertola, A; Musto, P; Caravita, T; Callea, V; Cangialosi, C; Liberati, Anna Marina
Sequential brief chemo-immunotherapy FND plus rituximab in elderly patients with advanced stage follicular lymphoma (FL): High clinical and molecular remission rate associated with a prolonged failure-free survival.
2004 Vitolo, U; Boccomini, C; Ladetto, M; Pogliani, E; Scalabrini, Dr; Tarella, C; Castellino, C; Aglietta, M; Atolfi, M; Carpaneto, A; Corradini, P; Darbesio, A; De Crescenzo, A; Levis, A; Liberati, Anna Marina
Concurrent Rituximab with dose-dense MegaCEOP chemotherapy and high dose mitoxantrone, ara-c and dexamethasone (MAD) followed by BEAM and autologous stem cell transplantation (ASCT) is feasible and effective in high risk diffuse large B-cell lymphoma (B-DLCL): A multicenter pilot study.
2004 Vitolo, U; Liberati, Anna Marina
Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.
2004 Morschhauser, F; Huglo, D; Martinelli, G; Paganelli, G; Zinzani, Pl; Hadjiyiannakis, D; Liberati, Anna Marina; Et, All
Improved safety profile of tumor-targeted taxane: an integrated safety summary of paclitaxel poliglumex (CT-2103) phase 1 and 2 trials
2004 P., Barbieri; F., Oldham; J., Holman; Liberati, Anna Marina
Features of relapsed disease in lymphocyte predominant Hodgkin's disease patients
2005 Liberati, Anna Marina; Cerroni, P; Zanotti, R; Spina, M; Viviani, S; Cervetti, G; Stelitano, C; Ferrara, P; Merluzzi, M; Vitolo, U.
Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis
2005 Botto, B; Vitolo, U; Cortelazzo, S; Chiappella, A; Allione, B; Angelucci, E; Boccomini, C; Cabras, Mg; Ceccarelli, M; Ciccone, G; Di Vito, F; Falchi, L; Guarini, A; Liberati, Anna Marina
Molecular response of CML patients to INF alpha based treatment or to STI based therapy.
2005 Luzi, D; Capozzi, R; Rauco, A; Pace, R; Donti, E; Gottardi, E; Bassetti, A.; Schippa, M; Saglio, G; Liberati, Anna Marina
Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec.
2005 Falchi, L; Desantis, G.; Liberati, F; Pace, R; Morandi, Mg; Scaravaglio, P; Saglio, G; Liberati, Anna Marina
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD)
2005 Rauco, A; Liberati, F; Capozzi, R; Morandi, Mg; Pace, R; Capparella, V; Cianciulli, M; Liberati, Anna Marina
Has the Ga-67-SPET a role in monitoring Hodgkin and primary mediastinal lymphoma in the PET-FDG age?
2005 Palumbo, Isabella; Desantis, G; Palumbo, Barbara; Falchi, L; Cerroni, P; Capparella, V; Cianciulli, M; Palumbo, R; Liberati, Anna Marina
Effect of adding Rituximab (R) to induction treatment and high dose chemotherapy (HDC) prior to autologous stem cell transplantation (ASCT) as first line therapy in stage III-IV diffuse large B-cell lymphoma (B-DLCL) at poor prognosis
2005 Vitolo, U; Rossi, G; Cabras, Mg; Liberati, Anna Marina
Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial.
2005 Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All
Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)
2005 F., Morschhauser; D., Huglo; G., Martinelli; G., Paganelli; P., Zinzani; D., Hadjiyiannakis; Liberati, Anna Marina; T., Illidge; N., Milpied; J., Kalmus; P., Morel; U., Reimann; R., Marcus
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) regimen as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (gisl)
2005 N. D., Renzo; M., Brugiatelli; A., Montanini; M., Dell'Olio; M., Petrini; C., Stelitano; Liberati, Anna Marina; S., Luminari; S., Morandi; G., Giglio; M., Federico
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista2371
Data di pubblicazione
- 2020 - 2026108
- 2010 - 20191001
- 2000 - 2009960
- 1990 - 1999256
- 1980 - 198942
- 1973 - 19794
Editore
- Springer Verlag Germany:Tiergarte...11
- Edizioni Minerva Medica:Corso Bra...5
- Editore attuale:BLACKWELL PUBLISH...2
- -Milano: Istituto nazionale per t...1
- Attuale:OXFORD UNIV PRESS, GREAT ...1
- BMJ Publishing Group, London1
- Elsevier Science Limited:Oxford F...1
- EWRR1
- Macmillan Magazines Limited:Porte...1
- Mary Ann Liebert Incorporated:2 M...1
Rivista
- BLOOD115
- HAEMATOLOGICA83
- NEUROUROLOGY AND URODYNAMICS80
- EUROPEAN UROLOGY. SUPPLEMENTS75
- GASTROENTEROLOGY75
- THE JOURNAL OF UROLOGY66
- URODINAMICA64
- JOURNAL OF PLANT PATHOLOGY45
- ANNALS OF THE RHEUMATIC DISEASES43
- BLOOD TRANSFUSION40
Keyword
- female urology32
- urinary incontinence30
- urodynamics28
- surgery27
- pelvic organ prolapse18
- stress urinary incontinence15
- voiding dysfunction13
- botulinum a toxin12
- resiniferatoxin12
- prostate cancer11
Lingua
- eng1615
- ita153
- enm1
- fre1
Accesso al fulltext
- no fulltext2371